Glucosamine Linked to Alzheimer's Progression
Analysis based on 18 articles · First reported Jun 09, 2026 · Last updated Jun 11, 2026
The research linking Glucosamine to accelerated Alzheimer s disease progression could negatively impact companies producing Glucosamine supplements, potentially leading to decreased sales and stock price declines. Conversely, pharmaceutical and biotechnology companies developing treatments for Alzheimer s disease, especially those targeting metabolic pathways, may see increased investor interest and funding opportunities.
New research from the University of Florida has found a concerning association between taking Glucosamine, a popular over-the-counter supplement for joint pain, and a higher likelihood of progressing from mild cognitive impairment to Alzheimer s disease. The study, published in Nature Metabolism, also linked Glucosamine use to a 25% increase in mortality risk among patients already diagnosed with Alzheimer s disease. Led by Ramon Sun, Ph.D., the research involved a retrospective analysis of UF Health records using artificial intelligence, as well as supporting data from advanced imaging of human brain specimens and Alzheimer s disease mouse models. The findings suggest that Glucosamine may exacerbate neurodegenerative decline by interacting with an overactive protein and sugar-tagging pathway (hyperglycosylation) in the Alzheimer's brain. While preliminary and requiring clinical trial validation, the study highlights metabolic dysfunction as a significant contributor to Alzheimer s disease progression and raises important questions about the safety of Glucosamine for older adults at risk of cognitive decline.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard